William M Pardridge
Pardridge, William M.
VIAF ID: 59156282 (Personal)
Permalink: http://viaf.org/viaf/59156282
Preferred Forms
- 200 _ | ‡a Pardridge ‡b William M.
-
- 100 1 0 ‡a Pardridge, William M.
- 100 1 _ ‡a Pardridge, William M.
-
-
-
- 100 1 _ ‡a Pardridge, William M.
- 100 1 _ ‡a Pardridge, William M.
-
- 100 0 _ ‡a William M Pardridge
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Brain drug targeting : the future of brain drug development | |
Introduction to the blood-brain barrier : methodology, biology, and pathology | |
Peptide drug delivery to the brain | |
Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice | |
Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. | |
Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery | |
Phenylalanine transport at the human blood-brain barrier. Studies with isolated human brain capillaries. | |
Predominant low-molecular-weight proteins in isolated brain capillaries are histones | |
Preferential Release of Triiodothyronine: An Intrathyroidal Adaptation to Reduced Serum Thyroxine in Aging Rats | |
Preparation of Trojan horse liposomes | |
Protamine-mediated transport of albumin into brain and other organs of the rat. Binding and endocytosis of protamine-albumin complex by microvascular endothelium | |
Rapid sequestration and degradation of somatostatin analogues by isolated brain microvessels. | |
Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse | |
Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain | |
Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. | |
Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes | |
Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse | |
Reduction of testosterone availability to 5α-reductase by human sex hormone-binding globulin in the rat ventral prostate gland in vivo | |
The Ro52/SS-A autoantigen has elevated expression at the brain microvasculature. | |
The safety of aspartame | |
Sarcolemmal protein profiles from cultured myotubes and myoblasts | |
Selective expression of the large neutral amino acid transporter at the blood-brain barrier | |
Serum bioavailability of sex steroid hormones | |
Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1. | |
Strategies to advance translational research into brain barriers | |
Synthesis and bioactivity of monobiotinylated DALDA: a mu-specific opioid peptide designed for targeted brain delivery. | |
Targeting neurotherapeutic agents through the blood-brain barrier | |
Targeting of an anti-CR3 (CD11b/CD18) monoclonal antibody to spleen but not brain, in vivo in mice. | |
Thyroid function in nonthyroidal illnesses | |
Tracer kinetic model of blood-brain barrier transport of plasma protein-bound ligands. Empiric testing of the free hormone hypothesis | |
Transferrin-antibody fusion proteins are effective in brain targeting | |
Translational science: what is it and why is it so important? | |
Transport of human recombinant brain-derived neurotrophic factor | |
Transport of insulin-related peptides and glucose across the blood-brain barrier | |
Transport of propranolol and lidocaine through the rat blood-brain barrier. Primary role of globulin-bound drug | |
Transport of protein-bound steroid hormones into liver in vivo. | |
Treatment of Alzheimer's Disease and Blood-Brain Barrier Drug Delivery | |
Treatment of human immunodeficiency virus-infected lymphocytes with cationized human immunoglobulins | |
Treatment of large solid tumors in mice with daunomycin-loaded sterically stabilized liposomes | |
Triiodothyronine bound to red blood cells is not available for transport through the blood-brain barrier | |
The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier | |
Tryptophan transport through the blood-brain barrier: In vivo measurement of free and albumin-bound amino acid | |
Tumor necrosis factor receptor-IgG fusion protein for targeted drug delivery across the human blood-brain barrier | |
Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy | |
Ultrastructural localization of blood-brain barrier-specific antibodies using immunogold-silver enhancement techniques. | |
Unidirectional influx of glutamine and other neutral amino acids into liver of fed and fasted rat in vivo. | |
Upregulation of blood-brain barrier GLUT1 glucose transporter protein and mRNA in experimental chronic hypoglycemia | |
Use of neutral avidin improves pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal antibody conjugate | |
Vascular genomics of the human brain | |
Vascular proteomics and subtractive antibody expression cloning | |
Vector-mediated delivery of a polyamide | |
Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey | |
Why is the global CNS pharmaceutical market so under-penetrated? | |
Widespread expression of an exogenous gene in the eye after intravenous administration. | |
William M. Pardridge, Recipient of the AAPS Meritorious Manuscript Award. | |
William Pardridge discusses the lack of BBB research. Interview by Rebecca N. Lawrence. |